Response of Peg IFN and Ribavarin in HIV-HCV Co-Infection

Background: Hepatitis C infection is one of most common co-infection in HIV. HIV infection influences the natural evolution of chronic hepatitis by higher rate of viral persistence, accelerating fibrosis, cirrhosis progressing to end-stage liver disease. Objective: This retrospective study was conducted in order to see the response to Peg- IFN α-2b with Ribavarin in HIV HCV co-infection. Material and Methods: Alanine aminotransferase and Aspartate Aminotransferase, HCV RNA quantitative and Genotype study, Fibroscan, CD4 were collected from the medical records of ART centre. Results: The mean baseline viral load (log10) was 5.76, 3.00 at 1 st month, 0.44 at 3 rd month, 0 at 6 th month and 12 th month. RVR was observed in 77.7%, EVR in 88.8%, SVR of 100% at 6 th and 12 th month. The mean OT and PT reduction at 3 rd month was 116.11(57.79%) and 132 (61.68%) respectively, at 6 month was 158 (78.65%) and 177.56 (82.97%) respectively, at 12 th month was 159(79.14%) and 176.56 (82.50%). Fibrosis at the start of treatment was 19.0 KPa, 10.00 KPa at 6 th month and 8.20 KPa at 12 th month. Conclusion: Study shows that SVR can be achieved in HCV HIV co infected patients with IFN and Ribavarin therapy which in turn reduces the morbidity and mortality due to liver disease. Inspite of virological response, few patients continue to have deranged AST and ALT and progressive liver fibrosis.